Target Pullback Viewed as Buying Opportunity and 4 Stock Analyses Not to Miss

Bristol-Myers Squibb Company (NYSE:BMY): Current price $36.90

Cowen raised their sales and earnings estimates for Bristol-Myers Squibb Company to reflect P&L leverage potential from new drugs including Eliquis. The firm noted that they did not have any estimates in their model for the failed prostate drug, Sprycel, but sees increase in new products. Shares are Outperform rated.

These stocks are hitting our Profit Targets. Click here now to discover winning stocks!